Bristol-Myers Squibb Company which can be found using ticker (BMY) have now 21 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $70.00 and $37.00 suggesting an average Analsyt target price of $61.24. Now with the previous closing price of $56.15 this would imply there is now a potential upside of 9.1%. Also worth taking note is the 50 day moving average now sits at $57.48 and the 200 day MA is $50.37. The company has a market cap of 113.58B. The price for the stock stands currently at: $55.97 USD
The potential market cap would be $123,884,265,247 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $23.41 and a 6.07% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
